{{Rsnum
|rsid=5945619
|Chromosome=X
|position=51498820
|Orientation=plus
|GMAF=0.2618
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 30.1 | 18.6 | 51.3
| HCB | 0.7 | 7.3 | 92.0
| JPT | 4.4 | 10.6 | 85.0
| YRI | 25.9 | 23.8 | 50.3
| ASW | 22.8 | 26.3 | 50.9
| CHB | 0.7 | 7.3 | 92.0
| CHD | 5.5 | 8.3 | 86.2
| GIH | 34.7 | 18.8 | 46.5
| LWK | 22.9 | 19.3 | 57.8
| MEX | 8.6 | 20.7 | 70.7
| MKK | 24.4 | 17.9 | 57.7
| TSI | 24.5 | 21.6 | 53.9
| HapMapRevision=28
}}

[http://cancergenetics.wordpress.com/2008/02/15/prostate-cancer-oldnew-snps-and-decodeprca/ cancer-genetics] these snps influence genetic risk for [[prostate cancer]]
*the [[haplotype]] [[rs6983267]] [[rs1016343]] [[rs4242384]] 
*[[rs7501939]] 
*[[rs1859962]]
*[[rs2660753]]
*[[rs9364554]]
*[[rs6465657]]
*[[rs10993994]]
*[[rs7931342]]
*[[rs2735839]]
*[[rs5945619]]
*[[rs10993994]]

{{PMID Auto
|PMID=19336566
|Title=Replication of the 10q11 and Xp11 Prostate Cancer Risk Variants: Results from a Utah Pedigree-Based Study.
|OA=1
}}
{{PMID Auto
|PMID=19366831
|Title=Analysis of Recently Identified Prostate Cancer Susceptibility Loci in a Population-based Study: Associations with Family History and Clinical Features
|OA=1
}}

{{PMID Auto GWAS
|PMID=18264097
|Trait=Prostate cancer
|Title=Multiple newly identified loci associated with prostate cancer susceptibility
|RiskAllele=C
|Pval=2.0000000000000001E-9
|OR=1.19
|ORtxt=[1.07-1.31]
}}

{{PMID Auto
|PMID=19549809
|Title=Fine-Mapping and Family-Based Association Analyses of Prostate Cancer Risk Variants at Xp11
|OA=1
}}

{{omim
|desc=PROSTATE CANCER, HEREDITARY, X-LINKED 2; HPCX2
|id=300704
|rsnum=5945619
}}

{{PMID|18708398|OA=1
}} Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium.

{{PMID|18794092|OA=1
}} Association of prostate cancer risk variants with clinicopathologic characteristics of the disease.

{{PMID|18974127|OA=1
}} Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer.

{{PMID|19104501|OA=1
}} Prostate cancer genomics: towards a new understanding.

{{PMID|19434657|OA=1
}} Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.

{{PMID|19549807|OA=1
}} Prostate cancer risk associated loci in African Americans.

{{PMID|19639606|OA=1
}} Correcting "winner's curse" in odds ratios from genomewide association findings for major complex human diseases.

{{PMID|20039378|OA=1
}} Estimation of genotype relative risks from pedigree data by retrospective likelihoods.

{{PMID|20690139}} Meta-analysis of genome-wide and replication association studies on prostate cancer.

{{PMID|21071540|OA=1
}} Validation of genome-wide prostate cancer associations in men of African descent.

{{PMID|21390317|OA=1
}} Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers--results from BPC3.

{{PMID|21538423|OA=1
}} Early onset prostate cancer has a significant genetic component.

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs5945619
|overall_frequency_n=59
|overall_frequency_d=92
|overall_frequency=0.641304
|n_genomes=42
|n_genomes_annotated=0
|n_haplomes=78
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}